PRESS RELEASES

Cannformatics and Dr. Laszlo Mechtler Announce Intent to Launch Lab Service for Personalized Medical Cannabis in Migraine and Other Conditions

Cannformatics to Announce Dementia and Medical Cannabis Study at the 2nd Annual New York State Medical Cannabis Symposium

Cannformatics Announces Scientific Reports Publication Revealing Groundbreaking Progress in Personalizing Medical Cannabis Treatment for Autism Spectrum Disorder

Cannformatics Unlocks Medical Cannabis' Mechanism of Action In Children with Autism Spectrum Disorder. Second Paper Published from Autism Pilot Study.

Cannformatics Announces Publication of Groundbreaking Study Identifying Cannabis-

Responsive™ Biomarkers In Children with Autism Spectrum Disorder

Cannformatics and Cannabotech Announce the First Clinical Study Using Cannabis-Responsive™ Biomarkers to Evaluate the Impact of "MycoCann NeuroPain" in Managing Chronic Neuropathic Pain

Cannformatics Strengthens Its Advisory Board with Appointment of Medical Cannabis Expert and Physician Bonni Goldstein, M.D.

Former U.S. Congressman Edward Feighan Joins Cannformatics Advisory Board

Three Pioneers In Using Medical Cannabis For Treating Autism Spectrum Disorder Come Together To Sponsor Cannformatics' ASD Pilot Study

Cannformatics Receives Approval For Pilot Study Identifying Cannabis-Responsive™ Biomarkers In Children With Autism

Biotechnology Startup Cannformatics Expands Advisory Board with Nationally Recognized Experts in Clinical Medicine and Pediatric Neuropsychology